Cell Signaling Technology Logo
1% for the planet logo
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

PDE3A (F7I6O) Rabbit mAb #23920

Filter:
  • WB

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 136, 118
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Simple Western™ 1:10 - 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    PDE3A (F7I6O) Rabbit mAb recognizes endogenous levels of total PDE3A protein. This antibody recognizes PDE3A1 and PDE3A2 isoforms but does not recognize PDE3A3 isoform.


    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val395 of human PDE3A1 protein.

    Background

    PDE3A is a member of the cyclic nucleotide phosphodiesterase (PDE) superfamily (1). The protein is a cAMP phosphodiesterase inhibited by cGMP. PDE3A regulates cAMP-activated signaling pathways through hydrolysis of cAMP (2). There are three isoforms of PDE3A: PDE3A1 (136 kDa), PDE3A2 (118 kDa), and PDE3A3 (94 kDa). They are generated by alternative splicing of the PDE3A gene. All PDE3A isoforms share the same catalytic domain and promote cAMP hydrolysis in distinct but overlapped intracellular compartments (3). PDE3A has been shown to promote platelet aggregation, pulmonary thrombosis, and increased heart rate (4). The elevated phosphodiesterase activity from gain-of-function mutations in the PDE3A gene leads to hypertension without cardiac damage (5). The compound DNMDP and synthetic molecular glue molecules promote PDE3A/Schlafen 12 (SLFN12) heterotetrameric complex formation, leading to a cytotoxic response in cancer cells that express high levels of these two proteins. Inducing this complex formation poses a potential therapeutic treatment in human cancer (6-8).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.